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Abstract
Background: Interstitial deletions of the long arm of chromosome 14 involving the 14q24-q32 region have been
reported in less than 20 patients. Previous studies mainly attempted to delineate recognizable facial dysmorphisms;
conversely, descriptions on neurological features are limited to the presence of cognitive and motor delay, but no
better characterization exists.
Case presentation: In this paper we report on a patient with a de novo interstitial deletion of 5.5 Mb at 14q24.3-
q31.1. The deletion encompasses 84 genes, including fourteen Mendelian genes. He presented with dysmorphic
face, developmental delay, paroxysmal non-epileptic events and, subsequently, epilepsy.
Conclusions: The clinical and molecular evaluation of this patient and the review of the literature expand the
phenotype of 14q23-q32 deletion syndrome to include paroxysmal non-epileptic events and infantile-onset focal
seizures.
Keywords: 14q, microdeletion, epilepsy, myoclonus, EEG, seizures
Background
Interstitial deletions of the long arm of chromosome 14
involving the 14q24-q32 region have been reported in
less than 20 patients [1–11]. Previous studies on patients
with 14q interstitial deletions mainly attempted to delin-
eate recognizable facial dysmorphisms; conversely, de-
scriptions on neurological features are limited to the
presence of cognitive and motor delay, but no better
characterization exists [9].
In this paper we report on a patient with a de novo
interstitial deletion at 14q24.3-q31.1. We aim to underlie
his neurological features comparing them with those ob-
served in patients carrying similar deletions.
Case presentation
This 2-year-old boy was the third son of non-
consanguineous healthy Italian parents. He was born at
the fortieth gestational week after an uneventful preg-
nancy and a spontaneous delivery. Family history was
negative for neurological diseases or congenital birth
defects. One and five minute Apgar scores were respect-
ively 9 and 10. Birth weight was 3450 g (35–50th per-
centile), birth length was 55 cm (97th percentile) and
head circumference was 33 cm (10th percentile). At
birth, bilateral metatarsus varus was evident, requiring
conservative orthopedic treatment. No further bone de-
formities were noticed. He was referred to our attention
at age of 8 months for daily, brief episodes of generalized
hypertonia and staring. Dysmorphic features of the face
were observed, such as arched eyebrows, down-slanting
palpebral fissures, anteverted nostrils, depressed nasal
bridge, wide philtrum, and arched thin upper lip (Fig. 1).
A single cafè-au-lait spot was present on left thigh.
Neurological evaluation showed axial hypotonia. Micro-
cephaly was not present. Developmental milestones were
mildly delayed: the baby controlled his head at age
5 months, but could not be seated without support. An
ictal video-electroencephalogram (EEG) revealed normal
findings for age and excluded an epileptic origin of the
events. Subsequently, at the age of 9 months, he devel-
oped daily episodes of psychomotor arrest, palpebral
myoclonias, oral automatisms (e.g., chewing) rarely
coupled with vibratory hypertonus. Sleep and awake
interictal video-EEGs showed a normal background activity
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with epileptiform anomalies in bilateral central regions.
Therapy with levetiracetam was started and titrated to
40 mg/kg/day. Brain magnetic resonance imaging revealed
corpus callosum hypoplasia and enlargement of fronto-
temporal sub-arachnoids spaces. Cardiac, abdominal and
pelvic (including liver, spleen, gall bladder, pancreas and
bladder) ultrasound findings were unremarkable. Eye
examination revealed no abnormalities. Routinary bio-
chemical analysis, electrocardiogram, auditory brainstem
response and visual evoked potential and electroretino-
gram yielded normal results. Valproic acid (30 mg/kg/die)
and, successively, clonazepam (0.6 mg/die) were added to
levetiracetam since daily seizures persisted.
At last follow-up the child is 2 year old. Seizures are
controlled by levetiracetam, valproic acid and clonazepam
and recurred twice during febrile episodes. Language delay
is present: he is able to pronounce 3–5 words. Motor devel-
opment is improved: he can stand and walk autonomously.
Materials and methods
Blood was obtained from the proband and his parents
after signed informed consent. Genomic DNA was isolated
from peripheral blood lymphocytes by using BioRobot EZ1
(Quiagen, Solna, Sweden). DNA concentration and purity
were determined with a ND-1000 Spectrophotometer
(NanoDrop Technologies, Berlin, Germany), while for the
detection of submicroscopic genomic imbalances, we typed
genomic DNA by using the Genome-Wide Human SNP
6.0 Array (Affymetrix, Santa Clara, Calif., USA), including
1.8 M oligonucleotide markers, as previously described
[12]. Microarrays were washed and stained with the Affy-
metrix Fluidics Station 450 and scanned with the Affyme-
trix GeneChip Scanner 3000 using the Command Console
software (Affymetrix). Copy number analysis was per-
formed with the Genotyping Console software version 4.1
(Affymetrix) using annotation file version NA32 (hg19)
and an in-house reference file consisting of 90 samples.
Physical mapping and gene locations were obtained from
the University of California Santa Cruz (UCSC, http://
genome.ucsc.edu/cgi-bin/hgGateway) Genome Browser,
assembly GRCh37.
The SNP array analysis revealed a deletion of
approximately 5.5 Mb at 14q24.3-q31.1 region
(73,939,744x2,73,939,850-79,446,043x1,79,446,101x2).
The deletion was absent in the parents, indicating a
de novo origin of the rearrangement. The deletion encom-
passes 84 RefSeq genes (hg19; http://genome.ucsc.edu//).
Discussion
Deletions of the 14q24-q32 region vary in size (ranging
from approximately 10 to 20 Mb) and involve several
RefSeq genes resulting in a non-specific dysmorphic ap-
pearance associated with neurological involvement of
somewhat variable gravity [11]. Attempt to identify a
well-detailed genotype-phenotype correlation is hindered
by: (1) a few number of published patients; (2) an
inaccurate mapping of the deleted segment and lack of
detailed breakpoints due to the use of karyotypes or
FISH before the era of high-resolution cytogenetic; (3)
an association, in previous reviews, of patients with 14q
deletions different in size and location; (4) a paucity of
data regarding some relevant aspects such as neuro-
logical features.
The patient herein reported showed most of the dys-
morphic features which have been coupled with the
14q24-q32 deletion, such as hypertelorism, inner epican-
thic folds, short and bulbous nose with a depressed
bridge, thin upper lip, ears anomalies, pointed chin and
micrognathia [11]. No malformations of internal organs
were discovered, thus being in line with former reports,
which identified heart anomalies in three children [9,
11]. Our case harbored the smallest deletion of the
14q24-q32 region (i.e., 5.5 Mb) reported to date. This re-
gion contains several genes whose mutations are known
to cause well-defined conditions (Table 1). However,
characteristic findings for these entities are currently not
present in our patient because most of them are auto-
somal recessive disorders.
Fig. 1 Our patient at 6 months of age: arched eyebrows, down-slanting
palpebral fissures, anteverted nostrils, depressed nasal bridge,
wide philtrum, and arched thin upper lip
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Clinical picture of our case was primarily dominated
by neurological involvement. He presented with hypo-
tonia, mild-to-moderate global developmental and lan-
guage delay, and paroxysmal episodes of non-epileptic
and, successively, epileptic origin. Neurological features
of previously described patients are shown in Table 2.
Although neurological data have been frequently missed
by other authors, mild-to-moderate global developmen-
tal delay has been reported in majority of cases and
hypotonia has been described in at least 50 % of cases.
Additionally, language delay has been reported in 10 out
of 14 cases, with four cases able to pronounce no words.
Microcephaly was discovered in 50 % of patients. As
regards epilepsy, one patient presented a single febrile
seizure and another one a single afebrile seizure.
Schlade-Bartusiak et al. [8] reported one case with focal
epilepsy and temporo-occipital anomalies on EEG. Our
patient showed infantile-onset focal epilepsy, which re-
quired polytherapy. Notably, epilepsy appeared closely
with paroxysmal non-epileptic events. Previously, Ono et
al. [6] reported a case of 14q24-q32 deletion and non-
epileptic myoclonus status developed at age of 18 months.
Although epilepsy and paroxysmal non-epileptic events
are both limited to two out of 14 cases (15 %), clinicians,
managing patients with 14q24-q32 deletion, should be
aware that similar manifestations can appear and require
specific investigations, as EEG or neuroimaging, and treat-
ment. However, brain imaging revealed nonspecific find-
ings, such as atrophy, ventricles or subarachnoid spaces
enlargement, and corpus callosum hypoplasia, but not
neuronal migration disorders.
From a genetic point of view, the chromosome 14 is
involved in several single-gene as well as microdeletion
diseases. In fact, patients with ring 14, 14q11-q13 dele-
tion, 14q24.1-q24.3 deletion, 14q24-q32 deletion, and
14q32 deletion have been reported [13]. Currently, a full
distinction between these forms is not available due to
the few patients reported for each condition, with the
exception of ring 14 syndrome. The ring 14 syndrome is
characterized by a more severe clinical picture, with
postnatal growth delay, microcephaly, minor facial
anomalies, eye involvement with retinal degeneration,
drug-resistant epilepsy, and cognitive delay with speech
problems [10]. Patients with 14q11-q13 deletion have
microcephaly, corpus callosum anomalies, gastrointes-
tinal anomalies and, in smaller percentage, vision loss
secondary to cortical blindness and/or optic nerve atro-
phy, seizures, recurrent infections, and genitourinary
Table 1 OMIM genes deleted in our patient, with related phenotypes and model of inheritance
Gene OMIM Phenotype Inheritance
DNAL1 610062 Ciliary dyskinesia, primary, 16 AR
ALDH6A1 603178 Methylmalonate semialdehyde dehydrogenase deficiency AR
VSX2 142993 Microphthalmia with coloboma; AR
Microphthalmia, isolated 2
LTBP2 602091 Glaucoma 3, primary congenital, D; AR
Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma;
Weill-Marchesani syndrome 3, recessive
EIF2B2 606454 Leukoencephalopathy with vanishing white matter; AR
Ovarioleukodystrophy
MLH3 604395 Colorectal cancer, hereditary nonpolyposis, type 7; AD
Colorectal cancer, somatic
FLVCR2 610865 Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome AR
TGFB3 190230 Rienhoff syndrome; AD
Arrhythmogenic right ventricular dysplasia 1
IFT43 614068 Cranioectodermal dysplasia 3 AR
ESRRB 602167 Deafness, autosomal recessive 35 AR
POMT2 607439 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2; AR
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2;
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2
VIPAS39 613401 Arthrogryposis, renal dysfunction, and cholestasis 2 AR
SPTLC2 605713 Neuropathy, hereditary sensory and autonomic, type IC AD
NPC2 601015 Niemann-Pick disease, type C2 AR
List of abbreviations: AD autosomal dominant, AR autosomal recessive
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Table 2 Summary of the neurological and cytogenetic features of published patients harboring a 14q23-q32 interstitial deletion




























NR Yes No Normal NR NR NR
2- Kawamura
et al., 1985 [2]









et al., 1986 [3]
M 10mo –
12ya
14q24.3-32.1 NA Yes (−1.7 SD) Yes Mild Yes Mild NR No
languagea




4- Rivera et al.,
1992 [4] (P1)
M 1y 3mo 14q24-q32 NA Yes (<3 %) NR Yes Mild NR No words
at 15 mo
NR NR NR NR NR
5- Byth et al.
1995 [5]
(P1251)
F NR 14q23-q32 11.6 MB
(76,822,337–
88,488,190)b
No Yes Mild Yes Mild NR NR NR NR NR NR NR
6- Byth et al.
1995 [5]
(P1141)
F 5y 14q24.1-q31 NA Yes Yes No NR NR NR NR NR NR NR
7- Ono et al.,
1999 [6]












































F 5y 14q24-3q32.1 18.5 Mb
(77,823,431–
96,400,270)b
















F 19y 14q24.3q32.12 13.9 Mb
(77,867,749–
91,848,982)b




















M 18y 14q24.3q32.13 20.9 Mb
(73,942,355–
94,914,188)b







M 10y 14q24.3-q32.2 21.5 Mb
(77,226,431–
98,771,224)b
No Yes Yes Yes No
language
NR NR NR NR NR
13 – Riegel
et al., 2014 [11]
M 6y 9mo 14q24.3-q31.3 13.1 Mb
(76,822,337–
88,488,190)b





14- This report M 2y 1mo 14q24.3-q31.1 5,5 Mb
(73,939,850–
79,446,043)















List of abbreviations: M male, F female, y years, mo months, NA not applicable, NR not reported, SD standard deviation, CT computed tomography, MRI magnetic resonance imaging, ABR auditory brainstem response, T
temporal, O occipital, C central
aAdditional information on these two patients were reported by Ono et al. [6] on the basis of personal communications by Kawamura and Yamamoto












and renal abnormalities [14]. Deletion of the 14q24.1-
q24.3 region has been coupled with congenital heart de-
fects, brachydactyly, mild intellectual disability, and facial
dysmorphic signs [15]. Finally, mental retardation, hypo-
tonia, postnatal growth retardation and dysmorphic fea-
tures have been observed in patients with 14q32 deletion
[13]. Previously, other authors attempted to create a dele-
tion map to establish genotype-phenotype correlation in
14q interstitial deletions [9, 10]. In particular, Cingoz and
colleagues suggested that haploinsufficiency of Neurexin 3
(NRXN3), a protein that function in the nervous system as
receptor and cell adhesion molecule and which has been
associated with autism, may underlie cognitive and neuro-
logical defects [9]. Focusing on the overlapped deleted
region in our and other patients with known breakpoints
(Fig. 2), we were able to identify a small region of approxi-
mately 1.6 Mb (chr14: 77,823,431-79,446,043), which is
shared by all eight patients. This region contains the
TMED8, SAMD15, NOXRED1, VIPAS39, ISM2, AHSA1,
SPTLC2, ALKBH1, C14orf178, SLIRP, SNW1, ADCK1,
and part of NRXN3 genes. Apart from VIPAS39 and
SPTLC2 – which are associated with a form of
arthrogryposis with renal dysfunction and cholestasis,
and with hereditary sensory and autonomic neur-
opathy, type IC (Table 2), respectively – other genes
are not known to cause specific phenotypes. Looking
for candidate genes, which might influence phenotype
of the patients, we focused on ALKBH1, a histone
H2A dioxygenase that regulates a subset of genes required
for neural development in embryonic stem cells [16].
We speculate that haploinsufficiency of ALKBH1 and
NRXN3 might contribute to neurological involvement
in 14q24-q32 deletion.
Conclusion
In summary, clinical findings of our patient are consist-
ent with those previously reported in cases of 14q24-q32
deletion. These are characterized by dysmorphic features
and neurological involvement with hypotonia, global de-
velopmental delay, and, in some cases, epilepsy. Analysis
Fig. 2 Representation of the 14q23-q32 genomic region (USCS GRCh37/hg19 assembly) and extension of deletion in our case and previously
reported patients with known deletion size (minimal deletion and base pairs are taken from Riegel et al. [11] The overlapped deleted region of
approximately 1.6 Mb (chr14: 77,823,431–79,446,043) has been marked
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of previous cases, with known deletion size, allowed us
to identify an overlapped deleted region of 1.6 Mb that con-
tains genes underlying phenotype. A better characterization
of these deletions by molecular cytogenetic techniques will
help us to make more precise genotype-phenotype correla-
tions. Long term follow-up of patients with these newly de-
scribed genomic syndromes will give essential information
for genetic counseling of patients with similar anomalies.
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